The Split Vote: UroGen and the FDA

When an FDA panel held her company’s future in the balance, UroGen Pharma CEO Liz Barrett refused to fold, even with the odds stacked, a plunging stock, and one vote deciding it all.PODCAST TEAMProducer and Director: Devon LeaverEditor: Dominique GuerraProduction Coordinator: YingYu LinProduction Support: Annabelle ChanStory Consultants: Partner & Research Analyst Tony Nguyen, and Chief Corporate Finance Officer, Chris Seiter.Featuring: Liz Barrett, President & CEO of UroGen Pharma, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP.FOLLOW USLove our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.CHAPTERS00:00 - Introduction00:54 – Liz Barrett’s pharma journey03:26 - UroGen: the product and the pipeline08:31 - The FDA vote on UroGen15:07 - UroGen and RTW’s relationship18:42 - Liz Barrett’s leadership style22:40 - OutroDISCLAIMERThis interview was given by Liz Barrett, President & CEO of UroGen Pharma, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.